News

Complementary alternative medication (CAM) including vitamins, herbals, supplements, homeopathy, and extracts seems to be as polarizing a topic as politics these days. Given that more than half of the US adult population uses at least 1 CAM, you can easily find passionate opinions on either side of the isle from the Herbal Tea Party and Abstinence Only factions.1 Children’s Hospital of Philadelphia (CHOP) recently fueled the debate by publically declaring they would no longer provide CAM.2 Families wishing to continue these agents during hospitalization have to sign a waiver and provide the product. Some hospitals have long held this abstinence policy (perhaps sans waiver), but were less vocal in their withdrawal. The motivation for disallowing use is based on risks to the patients due to the inherent unknowns of CAM. Patients seem to be increasingly motivated to continue consuming, however, as self-management with CAM skyrockets.

Continued use of statins may help prevent delirium in critically ill patients who received statins before hospital admission, according to a study published online ahead of print in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

Diabetic patients who used an online patient portal to refill medications increased their medication adherence and improved cholesterol levels, according to a Kaiser Permanente study published in a recent issue of Medical Care.

An analysis of emergency department (ED) visits over a 10-year period found that while inappropriate antibiotic use is decreasing in pediatric settings, it continues to remain a problem in adults, according to a study published ahead of print in Antimicrobial Agents and Chemotherapy.

In elderly patients with chronic lymphocytic leukemia (CLL) taking obinutuzumab (Gazyva, Genentech), also known as GA101, in combination with chlorambucil lived nearly 1 year longer without worsening of their disease compared to rituximab in combination with chlorambucil, according to a study published online ahead of print in the New England Journal of Medicine.

Major depressive disorder (MDD) is a medical illness that is characterized by depressed mood, hopelessness, and loss of interest.1 According to the National Institute of Mental Health (NIMH), approximately 6.7% of US adult population experienced MDD, with 30.4% of these cases (2.0% of U.S. adult population) classified as severe.

An investigational all-oral proteasome inhibitor-MLN9708 (Millennium: The Takeda Oncology Company)-plus lenalidomide and dexamethasone generated high response rates and increased depth of response with extended treatment duration in newly diagnosed multiple myeloma patients, according to data presented at the American Society of Hematology (ASH) 2013 annual meeting in New Orleans.